Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 11/09/23
Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis MeetingGlobeNewsWire • 11/02/23
Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in NovemberGlobeNewsWire • 10/26/23
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over TimeThe Motley Fool • 10/21/23
Intellia's (NTLA) IND for Gene-Editing Therapy Gets FDA ClearanceZacks Investment Research • 10/19/23
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene EditingInvestors Business Daily • 10/18/23
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with CardiomyopathyGlobeNewsWire • 10/18/23
Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary AngioedemaGlobeNewsWire • 10/13/23
Intellia (NTLA), Regeneron Expand Deal for Gene-Editing TherapiesZacks Investment Research • 10/04/23
Regeneron, Intellia Therapeutics expand research collaboration to make gene editing therapiesReuters • 10/03/23